The figure shows lack of strong evidence for vitamin D therapy to prevent cardiovascular disease in CKD. Although epidemiologic studies suggest a relationship.

Slides:

Advertisements

Similar presentations

 Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease:

Advertisements

Vitamins B, E, and Health Partha Paul Endocrinology Rounds.

NKF-KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease UPDATE OF HEMOGLOBIN TARGET Am.J.Kidney.Dis.

10/5/2015. Hypertension GuidelinesDate JNC JNC JNC NICE Guidelines 2011 ESC / ESH Hypertension Guidelines ESC Guideline2007.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.

Answering Clinical Questions at the Point of Care 鄭如雅

Chapter 1: Definition and classification of CKD Kidney International Supplements Volume 3, Issue 1, Pages (January 2013) DOI: /kisup

Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med.

Hypothesis: an erythropoietin honeymoon phase exists

From: Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney DiseaseA Secondary Analysis.

LDL cholesterol in CKD—to treat or not to treat?

Copyright © 2000 American Medical Association. All rights reserved.

Nat. Rev. Cardiol. doi: /nrcardio

Because we would like to optimally individualize patient care, n-of-1 randomized clinical trials are at the top of the hierarchy of study designs, followed.

Current status of end-stage renal disease care in India and Pakistan

Suggested approach to patients with dabigatran-associated bleeding

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Figure 1.17 of the 2016 US Renal Data System Annual Data Report, Volume 2, chapter 1 showing the trends in the number of patients with incident ESRD (in.

Nat. Rev. Cardiol. doi: /nrcardio

Should chloride-rich crystalloids remain the mainstay of fluid resuscitation to prevent ‘pre-renal’ acute kidney injury?: con Dileep N. Lobo, Sherif.

Current status of end-stage renal disease care in India and Pakistan

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Vitamin D deficiency and heart disease

Evolving Gene Therapy in Primary Immunodeficiency

Prehypertension and chronic kidney disease: the ox or the plow?

Reassessment of the care of the patient with chronic kidney disease

John P. Middleton, Patrick H. Pun Kidney International

Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study1,2 Robert N. Foley, Charles A. Herzog, Allan.

Francesco Paolo Schena Kidney International

Chapter 3: Management of progression and complications of CKD

Need for better diabetes treatment for improved renal outcome

(A) Comparison of V, however estimated, to itself and to a transformation of V, Vt = 3.27 × V2/3 (see reference 42). (A) Comparison of V, however estimated,

Chapter 2: Use of iron to treat anemia in CKD

Volume 70, Pages S21-S25 (December 2006)

Volume 72, Issue 6, Pages (September 2007)

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Use of vitamin D in chronic kidney disease patients

LDL cholesterol in CKD—to treat or not to treat?

Volume 76, Pages S3-S8 (August 2009)

Volume 73, Issue 12, Pages (June 2008)

Volume 87, Issue 1, Pages (January 2015)

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Methods for guideline development

Volume 87, Issue 1, Pages (January 2015)

Hemodialysis patients represent a tiny subset of all patients with heart disease. Hemodialysis patients represent a tiny subset of all patients with heart.

Vitamin D in chronic kidney disease: is the jury in?

Volume 81, Issue 12, Pages (June 2012)

Carmine Zoccali, Francesca Mallamaci Kidney International

Volume 70, Issue 7, Pages (October 2006)

Volume 80, Issue 10, Pages (November 2011)

Cardiovascular risk in chronic kidney disease

Distribution of podocyte gene mutations in patients with genetic congenital nephrotic syndrome (CNS) and steroid–resistant nephrotic syndrome (SRNS). Distribution.

Algorithm for the management of patients with prediabetes or T2DM and definite NASH. This suggested therapeutic algorithm is based on the safety and efficacy.

Effect of sevelamer versus calcium-based binders on all-cause mortality in patients with CKD. Compared with calcium-based binders (CBBs), sevelamer significantly.

Longitudinal follow up of more than 300 dialysis patients who had PWV measurements performed in aorta, brachial/radial, and femoral/tibial vascular beds.

Antioxidant therapy in hemodialysis patients: a systematic review

Diagram of the mechanisms involved in limiting the ability of the kidney to maintain the levels of 1,25-dihydroxyvitamin D in chronic kidney disease (CKD).

Area under the curve (AUC)–targeted dosing of carboplatin using either the Cockcroft–Gault formula or the Chronic Kidney Disease Epidemiology Collaboration.

Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Patient factors that increase risk for drug-induced nephrotoxicity.

Authors’ concept of aortic stiffness in relation to other cardiovascular risk factors. Authors’ concept of aortic stiffness in relation to other cardiovascular.

Risk for chronic kidney disease (CKD) among Olmsted County, MN, stone formers and control subjects. Risk for chronic kidney disease (CKD) among Olmsted.

Mortality caused by cardiovascular disease (A) and sepsis (B) of patients with end-stage renal disease (ESRD) treated by dialysis compared with the general.

Volume 68, Issue 4, Pages (October 2005)

Dialysis limitations. Dialysis limitations. (A) Recent data from observational studies and randomized, clinical trials indicate significant limitations.

As the patient nears the end of life (dashed arrow), there is an increasing focus on symptom control and patient goals of care and a shift in the approach.

Mean number of dialysis sessions per patient for which intradialytic hypotension–related nursing interventions were required during the first 2 wk and.

Algorithm for routine management of mobility limitations in CKD

Presentation transcript:

The figure shows lack of strong evidence for vitamin D therapy to prevent cardiovascular disease in CKD. Although epidemiologic studies suggest a relationship between vitamin D deficiency and cardiovascular (CV) events, observational studies show improvemen... The figure shows lack of strong evidence for vitamin D therapy to prevent cardiovascular disease in CKD. Although epidemiologic studies suggest a relationship between vitamin D deficiency and cardiovascular (CV) events, observational studies show improvement with supplementation, and randomized studies show improved vascular function with supplementation. There is no randomized trial evidence to justify supplementation in patients with CKD patients to improve cardiovascular function in regular clinical care. Debasish Banerjee, and Vivekanand Jha CJASN 2019;14:932-934 ©2019 by American Society of Nephrology